BCP
PNT

Berylson Capital Partners’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Berylson Capital Partners’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-386,221
Closed -$2.97M – 38
2021
Q3 		$2.97M Hold
386,221
– – 1.37% 23
2021
Q2 		$3.97M Buy
+386,221
New +$3.93M 0.88% 39

Other funds holding PNT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Berylson Capital Partners's PNT Position: Q4 2021 in Review

Berylson Capital Partners sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2021, closing a stake of 386,221 shares — an estimated $2.97M sold.

Berylson Capital Partners first reported a position in PNT in Q2 2021 and held it in 2 quarters. The position peaked at $3.97M in Q2 2021. 55 funds tracked by Wall St. Rank hold PNT as of Q4 2021.

  • Berylson Capital Partners reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Berylson Capital Partners sold 386,221 POINT Biopharma Global Inc. Common Stock shares in Q4 2021, an estimated $2.97M.
  • Berylson Capital Partners first reported a position in POINT Biopharma Global Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Berylson Capital Partners's POINT Biopharma Global Inc. Common Stock position peaked at $3.97M in Q2 2021.
  • 55 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2021.

Based on Berylson Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.